Clinical effectiveness of tislelizumab plus TKI as first-line therapy in patients with metastatic renal cell carcinoma (mRCC): A real-world studyP. Dong, T. Huang, L. Jiang, W. Wei, X. Zheng,Z. Zhang, S. Guo, H. Han, F. ZhouANNALS OF ONCOLOGY（2023）引用 0|浏览2暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
